Successful treatment of oral itraconazole for infantile hemangiomas: A case series

• DOI: 10.1111/1346-8138.12724
• Publication Date: 2014-12-16T07:58:52Z
• Authors: Yuping Ran; Shuang Chen; Yalin Dai; Daoxian Kang; Jebina Lama; Xin Ran; Kaiwen Zhuang
• Keywords: Male; 03 medical and health sciences; Antifungal Agents; 0302 clinical medicine; Administration, Oral; Humans; Infant; Antineoplastic Agents; Female; Itraconazole; Hemangioma; 3. Good health

AbstractInfantile hemangiomas can present a therapeutic challenge to clinicians, especially when associated with severe pain and feeding difficulties. The standard therapeutic management includes corticosteroids and propranolol. However, the clinical response is not always satisfactory. We present six cases of infantile hemangiomas successfully treated with oral itraconazole approximately 5 mg/kg per day. In the first month, the red color of the lesions became a little lighter and the growth of the lesions was controlled in all cases. An obvious clinical improvement was noted in all cases during the 3‐month period, with 80–100% improvement in each patient at the end of the treatment, which was judged by both their parents and the dermatologists. Compliance with treatment instructions of oral itraconazole in infants was judged to be very good. Side‐effects were mild and limited. Although itraconazole can inhibit angiogenesis and tumor growth in vitro and in vivo associated with some cancers, further research is required to understand the pathogenesis of infantile hemangiomas and the mechanism of itraconazole.